Genfit Assesses Optimal Elafibranor NASH Combo Therapy Opportunity
Executive Summary
As it nears the Phase III data readout for elafibranor in NASH, Genfit plans combo therapy studies to determine if a GLP-1 analog or SGLT2 inhibitor would offer the best therapeutic synergy, market potential and partnership opportunity.
You may also be interested in...
Preparing For The NASH Market: A Conversation With Genfit Execs
As Genfit nears Phase III data for its NASH candidate elafibranor, it has promoted a new CEO and is working ahead on both an NDA filing and facing the commercial challenges of a new therapeutic space.
Boehringer Adds Yuhan’s First-In-Class Dual Agonist To NASH Portfolio
Yuhan reaches $870m NASH licensing-out deal with Boehringer, touting its competitiveness in the space after earlier alliance with Gilead. The collaboration for first-in-class GLP-1/FGF21 dual agonist is poised to beef up German firm's R&D expertise in cardiometabolic disease.
Deal Watch: Gilead Partners With Carna On Small Molecule IO Drug Development
Partnership will use Carna’s proprietary lipid kinase drug discovery platform, bringing another aspect to Gilead’s IO efforts. Catalent continues expansion by acquiring Novavax R&D assets; Genfit licenses elafibranor in China to Terns.